CA2274116A1 - Utilisations de thioredoxine - Google Patents

Utilisations de thioredoxine Download PDF

Info

Publication number
CA2274116A1
CA2274116A1 CA002274116A CA2274116A CA2274116A1 CA 2274116 A1 CA2274116 A1 CA 2274116A1 CA 002274116 A CA002274116 A CA 002274116A CA 2274116 A CA2274116 A CA 2274116A CA 2274116 A1 CA2274116 A1 CA 2274116A1
Authority
CA
Canada
Prior art keywords
thioredoxin
inhibitor
tumor growth
inhibiting tumor
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002274116A
Other languages
English (en)
Other versions
CA2274116C (fr
Inventor
Garth Powis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2274116A1 publication Critical patent/CA2274116A1/fr
Application granted granted Critical
Publication of CA2274116C publication Critical patent/CA2274116C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002274116A 1996-12-06 1997-12-05 Utilisations de thioredoxine Expired - Fee Related CA2274116C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3199596P 1996-12-06 1996-12-06
US60/031,995 1996-12-06
PCT/US1997/022292 WO1998024472A1 (fr) 1996-12-06 1997-12-05 Utilisations de thioredoxine

Publications (2)

Publication Number Publication Date
CA2274116A1 true CA2274116A1 (fr) 1998-06-11
CA2274116C CA2274116C (fr) 2009-05-05

Family

ID=21862543

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002274116A Expired - Fee Related CA2274116C (fr) 1996-12-06 1997-12-05 Utilisations de thioredoxine

Country Status (3)

Country Link
EP (1) EP0946192A1 (fr)
CA (1) CA2274116C (fr)
WO (1) WO1998024472A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552060B1 (en) 1997-08-11 2003-04-22 Prolx Pharmaceuticals, Inc. Asymmetric disulfides and methods of using same
US6372772B1 (en) 1997-08-01 2002-04-16 Prolx Pharmaceuticals Corporation Inhibitors of redox signaling and methods of using same
CN1302107C (zh) 1998-01-30 2007-02-28 吉倪塞思技术公司 与硫氧还蛋白或硫氧还蛋白还原酶基因互补的寡核苷酸序列以及将其用于调节细胞生长的方法
WO2004013283A2 (fr) * 2002-08-02 2004-02-12 University Of Rochester Mutants de thioredoxine et leur utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8903003D0 (sv) * 1989-09-12 1989-09-12 Astra Ab Novel medical use

Also Published As

Publication number Publication date
CA2274116C (fr) 2009-05-05
EP0946192A1 (fr) 1999-10-06
WO1998024472A1 (fr) 1998-06-11

Similar Documents

Publication Publication Date Title
AU3313589A (en) 17beta-n-monosubstituted carbamoyl or 17beta-acyl-4-aza- 5alpha-androst-1-en-3-ones as 5alpha reductase inhibitors
HU9401679D0 (en) Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors
IL108075A0 (en) Enzyme inhibitors
AU5533094A (en) Enzyme inhibitors
AU1301295A (en) Biocidal compositions and methods for treating commercial and recreational water
ZA972000B (en) Inhibition of proliferation of cells.
AU6097094A (en) Antisense polynucleotide inhibition of human growth factor-sensitive cancer cells
AU3901985A (en) Erythorbates as corrosion inhibitor in brine
WO1993021942A3 (fr) Utilisation d'inhibiteurs de metalloprotease matricielle (mmp)
EP0583074A3 (fr) Inhibiteur de l'enzyme de conversion de l'angiotensine et procédé pour le préparer.
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
AU3634695A (en) Surface active agents as gas hydrate inhibitors
AU3943793A (en) Methods of inhibiting or enhancing scar formation in the CNS
EP0601322A3 (fr) Inhibiteur de déaminase d'adénosine.
CY2483B1 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation.
EP0567088A3 (fr) Procédé de préparation d'un inhibiteur d'amylase.
AU5597098A (en) Inhibitors of the enzymatic activity of psa
AU3107795A (en) Inhibitors of the benzamidine type
EP0220107A3 (fr) Utilisation des inhibiteurs de l'enzyme convertissant l'angiotensine dans la dégénération maculaire
HK1033096A1 (en) Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculationdisorders
AU4249389A (en) Quinolyloxazole-2-ones useful as proteinkinase C inhibitors
EP0599514A3 (en) Pyranoquinoline derivatives as inhibitors of cell proliferation.
EP0858262A4 (fr) Inhibiteurs de thrombine
EP0656069A4 (fr) Inhibiteurs de la proliferation cellulaire, preparation et utilisation.
CA2274116A1 (fr) Utilisations de thioredoxine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed